Celldex Therapeutics, Inc. - 10-Q Filing
Celldex Therapeutics reported a net loss of $78.685 million for the three months ended March 31, 2026, compared to $53.796 million in the same period in 2025. The company generated $15,000 in total revenues, primarily from contracts and grants, down from $695,000 in 2025. Operating expenses increased to $84.45 million from $63.43 million year-over-year, driven by higher research and development costs. Basic and diluted net loss per share was $1.18, compared to $0.81 in the prior year.
Tickers: $CLDX